Introduction: The present study was conducted to evaluate the effects of Liraglutide on NAFLD in patients with type 2 diabetes mellitus (T2DM) with elevated transaminases.

Methods: A total of 62 patients (male-38, female-24) with age group of 30-75 years, treated with Liraglutide 1.2 mg/1.8 mg OD were included in the study. Selected clinical and demographic profile were recorded for all patients at baseline and follow-up. The hepatic steatosis was assessed using liver elastography (Fibroscan).

Results: After a mean follow-up of 26 weeks, in 62 patients (meeting appropriate present inclusion criteria), there was significant reduction in weight from 88.63±8.6 kg (Mean ± SD) to 80.47±6.7 kg (p<0.001), as computed by paired t-test. The Mc-Nemar’s test also demonstrated a significant higher proportion of patients with reversibility of stage of fibrosis from baseline to follow-up, p=0.003. This is accompanied by significant reduction in the AFRI score from a baseline median(IQR) of 1.84 (1.61-2.73) to 1.26(1.19-1.48) (p<0.001), as computed by Wilcoxon signed rank test. At baseline, 6 had fibrosis stage 2, of which 4 regressed to stage 1 and 2 had no significant fibrosis at baseline; 24 had stage 3 fibrosis, of which 20 regressed to stage 2, 2 to stage 1 and 2 had no significant fibrosis at follow-up. Remaining 32 had stage 4 fibrosis, of which 12 had stage 3, 18 had stage 2 and only 2 had stage 1 fibrosis at follow-up. ALT and AST decreased from 47.65±4.65 to 24.31±5.43 and 29.67±2.21 to 17.65±4.59 respectively. There was also significant improvement in glycaemic control with reduction in HbA1c from 8.56 ± 0.56% to 7.21 ± 0.34%, p<0.001 along with significant reduction in systolic blood pressure from 133.26±11.39 mmHg to 122.81±7.29 mmHg (p<0.001) and diastolic blood pressure from 87.17±6.04 mmHg to 82.91±4.33 mmHg (p<0.001).

Conclusion: Liraglutide significantly reduces hepatic fibrosis and effectively cause reversal of elevated transaminases along with weight loss and blood pressure reduction in addition to good glycaemic control.


D. Basu: None. S. Roy Chaudhuri: None. N. Deka: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at